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ABSTRACT
Introduction. Despite the availability of several therapeutic
options for metastatic breast cancer (MBC), no robust pre-
dictive factors are available to help clinical decision making.
Nevertheless, a decreasing benefit from first line to sub-
sequent lines of treatment is commonly observed. The aim of
this study was to assess the impact of benefit from first-line
therapy on outcome with subsequent lines.
Methods.Weanalyzed a consecutive series of 472MBCpatients
treated with chemotherapy (CT) and/or endocrine therapy (ET)
between 2004 and 2012.We evaluated progression-free survival
(PFS) at first (PFS1), second, third, and fourth therapeutic lines,
according to treatment (ET and/or CT) and tumor subtypes.
Results. In the whole cohort, median overall survival was 34
months, and median PFS1 was 9 months. A 6-month benefit
was shown by 289 patients (63.5%) at first line, 128 (40.5%) at
second line, 76 (33.8%) at third line, and 34 (23.3%) at fourth
line. Not having a 6-month benefit at PFS1was associatedwith
less chanceofbenefit at second line (odds ratio [OR]: 0.48;95%
confidence interval [CI]: 0.29–0.77, p5 .0026) and at any line
beyond first (OR: 0.39; 95% CI: 0.24–0.62, p , .0001). In the
total series, after stratification for tumor subtypes, a strong
predictive effect was observed among HER2-positive tumors
(OR: 0.2; 95% CI: 0.05–0.73, p5 .0152).
Conclusion. Our results suggest that the absence of at least a
6-monthbenefit in terms of PFSwith first-line therapypredicts
a reduced probability of benefit from subsequent therapeutic
lines,especially inHER2-positivedisease.TheOncologist2015;
20:719–724
Implications forPractice:This studysupportsevidence showing that theabsenceof a6-monthbenefit in termsofprogression-free
survivalwith first-line therapypredicts a lackof benefit fromsubsequent therapeutic lines inmetastatic breast cancer.The random
distribution of benefit experienced by a subset of the cohort further spurs an interest in identifying predictive factors capable of
identifying the most appropriate therapeutic strategy.
INTRODUCTION
Breast cancer (BC) is themost common cancer among women
worldwide,witha totalof232,670newcasesof invasiveBCand
40,000 deaths estimated to occur in the United States in 2014
[1]. In European countries, the total number of new cases and
cancer deaths from BC estimated in 2012 was 364.4 and
90.6 per 100,000, respectively. About 1 in 8 (12%) women will
develop invasive BC during their lifetime [1, 2].
Approximately 6%–10% of newly diagnosed BC cases are
metastatic, whereas 20%–50% of patients with early BC will
eventually develop metastatic disease [3].
In this setting, systemic treatment aims to maintain or
enhance quality of life and to delay further spread of disease,
prolonging survival. Nevertheless, metastatic breast cancer
(MBC) remains an incurable disease [4].
Estimating overall survival (OS) for women with MBC is
a compelling issue that oncologists have to face when dealing
with this tumor type. The median OS for women with MBC is
about 24 months, ranging from 6.3 months in the worst-case
scenario to 55.8 months in the best-case scenario [5]. BC is
ahighlyheterogeneousdiseaseconsistingofdifferent subtypes,
each exhibiting specific histopathological and biological fea-
tures, and variable clinical outcome and response to different
treatments. Based on these premises, it should come as no
surprise that different levels of understandingand treatment of
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these subtypes have been reached. HER2-positive disease is
a starkexampleof this variabilityofoutcomes: althoughaHER2-
positive tumor used to be associated with poor prognosis, the
development of anti-HER2 therapies has dramatically changed
the prognosis of patients with HER2-positive disease [6–8].
Sequential use of single agents is considered a standard
approachforpatientswithMBCand ispreferredmainlybecause
of reduced toxicity comparedwith combination chemotherapy,
with most women treated with multiple lines of therapy. All
therapeutic decisions are usually tailored, taking into account
several variables such as tumor burden, sites of the disease
(visceral vs. nonvisceral), HER2 status, hormone receptor
(HR) status, disease-free interval, age, and menopausal status.
Despite the availability of several therapeutic options for MBC,
there are no validated predictive factors of benefit for
treatments beyond first line that could help in choosing the
mostappropriatesequenceofdrugstouse ineachdifferentcase
[9, 10]. Moreover, although it is still unclear how the choice of
aspecific therapycan influencefurther treatments,datasuggest
that the durationofdisease control achievedwith initial lines of
treatment may affect the duration of benefit from subsequent
therapies[11].Giventhe impactofcancer-carecosts,thistopic is
increasingly important to promote the proper use of resources.
Limiting further chemotherapy for patients not experiencing
response to three consecutive regimens is among the strategies
suggested by the American Society of Clinical Oncology (ASCO)
to improve care and to reduce costs [12].
The aim of this study is to assess how the benefit gained
from first-line treatment may influence the outcome with
subsequent lines and to analyze and explore differences ac-
cording to tumor subtypes.
MATERIALS AND METHODS
Weanalyzed a consecutive series of 472MBC patients treated
at the Department of Oncology of the University Hospital of
Udine, Italy, between 2004 and 2012. Pathological and clinical
datawereextracted fromelectronicmedical recordsaccording
to strict privacy standards and anonymized before analysis.
Basedon this database, simplifiedBCprofilesweredefined
as follows:HRpositive (estrogen receptor [ER]orprogesterone
receptor [PR] positive, HER2 negative), HER2 positive (HER2
amplification or overexpression and any ER or PR status), and
triple negative (ER and PR negative, HER2 negative). The thre-
shold for HR positivity was set at 1% [13].
We collected data about chemotherapy (CT), endocrine
therapy (ET), and anti-HER2 therapy.
OS was defined as the time elapsed between the start of
treatment for metastatic disease and death or last follow-up.
Progression-free survival (PFS) was defined as the time elapsed
betweentreatmentinitiationandtumorprogressionordeathfrom
any cause, censoring patients who were lost to follow-up [14].
Three distinct analyseswere conducted, first, by counting both CT
and ET lines; second, by counting CT lines only; and third, by
counting ET lines only.We evaluated progression-free survival at
first (PFS1), second (PFS2), third (PFS3), and fourth (PFS4) lines of
treatment, according to treatment (ET and/or CT) and tumor
subtypes.Postprogressionsurvival(PPS)wasdefinedastheinterval
between progression at first line and death or last follow-up [15].
The clinical benefit achieved with each line of treatment
was defined as progression or deathmore than 6months after
starting a specific treatment.We evaluated the distribution of
clinical benefit for first, second, third, and fourth lines of
treatment. The threshold of 6 months for disease-control
duration was chosen arbitrarily on the basis of data in the
literature about mean value for median PFS1 (7.6 months) [5]
and itseasyapplication in clinical practice.Theanalysis focused
on odds ratio (OR) calculated to estimate the chance of having
a 6-month benefit from a line beyond the first if a 6-month
benefit was not observed at first line. Other potential pre-
dictors of therapeutic benefit beyond first line were also
evaluated through univariate and multivariate analyses.
Toevaluatethedifferent impactofnothaving6-monthbenefit
according to tumor subtypes, a subgroupanalysiswas conducted.
RESULTS
Patient and disease characteristics are reported in Table 1.
Data about treatment history, categorized according to the
drug’smechanismof action, are presented in Figure 1. Overall,
62.9% of patients had HR-positive disease, 24.8% had HER2-
positive disease, and 12.3% had triple-negative disease.
Themedian follow-up of the series was 46.7months. One-
third of patients were metastatic at diagnosis. Approximately
37% and 22% of patients had received anthracyclines and
taxanes, respectively, as part of adjuvant or neoadjuvant treat-
ment.Twenty-twopatients had received trastuzumab in either
the adjuvant or neoadjuvant setting.
Themedian numberof treatment lines forMBCwas 3 (range:
1–13). All patients included in this analysis received a first-line
treatment, and 335 (71%), 246 (52%), and 158 (33%) received
second, third, and fourth lines of therapy, respectively. The
numberof patients according to linesof treatment, distinguishing
Figure 1. Class of antineoplastic agents according to line of
treatment.
Abbreviation: 5-FU, 5-fluorouracil.
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the successive categories of treatments for the HR-positive
population (endocrine treatment or chemotherapy), is shown in
Figure2.Combinationchemotherapywaspreferred in82patients
(22.47%) as first-line treatment and subsequently in 28 patients
(12%) at second line, in 10 patients (6.25%) at third line, and in
9 patients (10.47%) at fourth CT line. Among patients with HR-
positive disease, endocrinemaintenance treatmentwas received
by16.72%(57of341) in first-line,5.22%(13of249) in second-line,
5.38% (10 of 186) in third-line, and 2.38% (3 of 126) in fourth-line
treatment. In the HER2-positive population, an anti-HER2 drug
was receivedby94%at first line, 57%at second line, 54% at third
line, and 42% at fourth CT line. Among patients with bone-
only metastatic disease, 37% (45 of 123) received radiother-
apy with palliative intent at one disease site or more.
In thewhole cohort,medianOSwas34months, andmedian
PFS1, PFS2, PFS3, and PFS4 were 9, 4.4, 4, and 3 months,
respectively. Median PFS1 for CT was 7.1 months, whereas
median PFS1 for ET was 9.5 months. Median PFS2, PFS3, and
PFS4 were respectively 3.7, 3.3, and 4.2 months in CT lines and
4.7, 3.9, and 4.2 months in ET lines (Table 2).
As expected, subgroupanalysis showedsignificantly shorter
PFS1 for triple-negative disease compared with HR- or HER2-
positive disease (3.8 vs. 9.9 months, p, .0001). PFS2 was also
significantly different between HR- and HER2-positive popula-
tions (4.3 vs. 6.4months,p5 .02) andbetweenpatientswith or
without triple-negative disease (2.3 vs. 4.8months, p, .0001).
A 6-month benefit was shown by 289 patients (63.5%) at
first line, 128 (40.5%) at second line, 76 (33.8%) at third line,
and 34 (23.3%) at fourth line (Table 2).
Amongpatientswho receivedat least four linesof treatment,
60% exhibited a linear distribution of therapeutic effect (i.e., no
benefit if therewas no benefit in the previous line), with only 4%
of patients experiencing a 6-month benefit across all four
lines (supplemental online Fig. 1). In the total series, the lack
of a 6-month benefit inPFS1wasassociatedwitha lackofbenefit
at second line (OR: 0.48; 95% confidence interval [CI]: 0.29–0.77;
p5 .0026)andatanylinebeyondfirst (OR:0.39;95%CI:0.24–0.62;
p, .0001).When CTonly was considered, patients who did not
achieve a 6-month benefit had less chance of benefit from second
line (OR: 0.45; 95% CI: 0.25–0.81; p5 .0072) and from any other
line beyond first (OR: 0.43; 95% CI: 0.2–0.7; p5 .0026).
A lackofbenefitat the firstET linedidnotaffect theoutcome
with secondorany subsequentET line. Subgroupanalysisbased
on tumor subtypes showed that not having a 6-month benefit
from first-line treatment influenced the chance of having a
6-monthbenefit fromsubsequent linesonlyamongpatientswith
Figure2. Clinical benefit for first, second, third, and fourth linesof
treatment observed linear (A) and scattered (B) distribution.
Table 1. Patient and disease characteristics
Characteristic n %
ER status 433
Positive ($1%) 339 78.3
Negative (,1%) 94 21.7
PR status 434
Positive ($1%) 275 63.3
Negative (,1%) 159 36.6
HER2 status (IHC and/or FISH tests) 420
Positive 89 21.2
Negative 328 78.1
Previous treatment for early disease 472
Chemotherapy 234 49.6
Endocrine therapy 234 49.6
Anti-HER2 22 4.7
Stage at diagnosis 471
M0 324 68.8
M1 147 31.2
Sites of metastasis 472
Bone only 123 26.1
Visceral 243 51.5
Lung 114 24.2
CNS 21 4.4
Liver 117 24.8
ECOG PS
At first line 425
$2 44 10.4
0–1 381 89.6
At second line 325
$2 38 11.7
0–1 287 88.3
At third line 241
$2 32 13.3
0–1 209 86.7
At fourth line 153
$2 20 13.1
0–1 133 86.9
Age at diagnosis of metastatic breast cancer: median, 63 years; 25th to
75th percentile, 53–73.
Abbreviations: CNS, central nervous system; ECOGPS, Eastern Cooperative
Oncology Group performance status; FISH, fluorescence in situ
hybridization; IHC, immunohistochemistry; MBC, metastatic breast cancer.
www.TheOncologist.com ©AlphaMed Press 2015
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HER2-positive tumors (Table 3). Supplemental online Figure 2
depicts the distribution of clinical benefit for first, second, third,
and fourth line of treatment according to tumor types.
Variables predicting benefit from subsequent treatments
maintained statistically significance in multivariate analysis
(Table 4).
In thewhole cohort, median PPSwas 18.3months (25th to
75th percentiles: 5.1–36.2months). Stratifying the population
by tumor subtypes, the median PPS was 18.7 months (25th to
75th percentiles: 6.8–38.3 months) among patients with
HER2-positive disease, 19.4 months (25th to 75th percentiles:
6.4–36.8 months) among patients with luminal disease, and
6 months (25th to 75th percentiles: 0.8–12.1 months) among
patientswith triple-negativedisease.FactorspredictingPPSon
multivariate analysis are reported in Table 5.
DISCUSSION
Most women with MBC receive multiple lines of treatment,
thanks to the wide availability of drugs beyond the first line.
Although improvementof survival over timecould beexplained
by the introduction of novel agents for MBC [16–18], choosing
the most appropriate therapeutic sequence—and the oppor-
tunity of commencing a new treatment in advanced lines—is
still largely outside evidence-based medicine. Moreover, no
robust predictive factors are currently available. Consequently,
in everyday clinical practice, decisions about treatment are
usually based on rough estimation of the expected benefit.
Although clinical experience may provide some support
for the use of lines beyond the first, data from the scienti-
fic literature are few. Furthermore, expected benefit from
advanced linesof therapy ismodestandevenmoreunlikely tobe
achieved if previous lines have provided benefits of short
duration. In fact, eribulin is the only chemotherapeutic agent
Table 2. Progression-free survival according to different lines
of treatment
Line na
Median
PFS
(months)
IQR
(25th–75th
percentile)
Patients
presenting
a6-monthbenefit,
n/n (%)b
All treatment
First 472 9.0 4.2–18.2 289/455 (63.5)
Second 335 4.4 2.5–10.6 128/316 (40.5)
Third 246 4.0 2.2–8.4 76/225 (33.8)
Fourth 158 3.0 2.0–6.1 34/146 (23.3)
Endocrine therapy
First 331 9.5 3.7–19.7 208/319 (65.2)
Second 180 4.7 2.7–10.4 66/170 (38.8)
Third 75 3.9 2.4–7.3 23/72 (31.9)
Fourth 22 4.2 1.5–10.6 8/14 (36.4)
Chemotherapy
First 367 7.1 3.5–14.4 187/347 (53.8)
Second 234 3.7 2.1–8.4 78/219 (35.6)
Third 160 3.3 2.1–5.7 30/219 (21.1)
Fourth 87 2.5 1.8–4.2 6/80 (7.5)
aSample includes censored and uncensored patients.
bSample includes patients in whom the event (i.e., obtaining a 6-month
benefit) occurred.
Abbreviations: IQR, interquartile range; PFS, progression-free survival.
Table 3. Influence of not having a 6-month benefit from
first-line treatment on chance of having a 6-month benefit
from subsequent lines
Probability of
benefit at
second line
Probability of
benefit at any
line beyond first
OR 95% CI OR 95% CI
Overall
Total 0.48 0.29–0.77 0.39 0.24–0.62
Chemotherapy 0.45 0.25–0.81 0.43 0.24–0.74
Endocrine therapy 0.80 0.41–1.56 0.91 0.47–1.75
HR-positive
Total 0.89 0.49–1.64 0.58 0.32–1.05
Chemotherapy 0.67 0.30–1.49 0.59 0.27–1.26
Endocrine therapy 1.24 0.58–2.67 1.24 0.58–2.65
HER2-positive
Total 0.20 0.05–0.73 0.14 0.04–0.53
Chemotherapy 0.24 0.06–0.90 0.21 0.06–0.79
Endocrine therapy NAa NAa 0.75 0.05–11.31
Triple negative
Total 0.19 0.02–2.5 0.41 0.05–3.53
Chemotherapy 0.17 0.01–2.18 0.35 0.04–3.09
Endocrine therapy NA NA NA NA
Subgroup analysis is based on tumor types.
aAnalysis not reliable because of small sample size.
Abbreviations: CI, confidence interval; HR, hormone receptor; NA, not
applicable; OR, odds ratio.
Table 4. Variables predicting benefit from subsequent
treatments (multivariate analysis)
Variable OR 95% CI p value
Overall lines
Having 6-month benefit (no vs. yes) 0.47 0.28 0.81 .0065
HR status (negative vs. positive) 0.24 0.10 0.55 .0008
HER2 status (negative vs. positive) 0.18 0.07 0.43 .0001
Visceral localization (no vs. yes) 1.91 1.13 3.24 .0162
CT lines only
Having 6-month benefit (no vs. yes) 0.40 0.22 0.75 .0065
HER2 status (negative vs. positive) 0.30 0.15 0.60 .0001
Abbreviations: CI, confidence interval; CT, chemotherapy; HR, hormone
receptor; OR, odds ratio.
Table 5. Variables predicting postprogression survival
(multivariate analysis)
Variable
Hazard
ratio 95% CI
p
value
Having 6-month benefit (no vs.yes) 1.25 0.90 1.73 .1790
HR-positive vs. HER2-positive 1.28 0.84 1.96 .2486
Triple negative vs. HER2-positive 3.54 1.91 6.57 .0001
ECOG PS at first line (1 vs. 0) 1.49 1.07 2.07 .0176
ECOG PS at first line ($2 vs. 0) 1.08 0.55 2.09 .8313
Visceral localization (yes vs. no) 1.55 1.13 2.12 .0064
Bold values indicate statistically significant results.
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative
Oncology Group performance status; HR, hormone receptor.
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that showed an OS gain in heavily pretreated patients with
MBC, as reported in the phase III EMBRACE trial (13.1 vs. 10.6
months; hazard ratio: 0.81; 95% CI: 0.66–0.99; p5 .041) [19].
Eribulin was not found to be cost effective in the treatment
of advanced breast cancer relative to treatment of physician
choice;however, incomparisontosomemoreexpensivebranded
drugs, eribulin appears to be cost effective [20].
Inourcohort, 60%ofpatientspresenteda lineardistribution
of treatmenteffect showingno furtherbenefitafterPFSofshort
duration (i.e., less than 6 months). In contrast, 40% of patients
gained benefit from treatment beyond first or second line
despite a lackof benefit fromprevious lines. Interestingly, these
results seem to question once more whether the decision-
makingprocesscanbebasedontheperformanceobservedwith
previous treatments. The random distribution of benefit, al-
though experienced by a minority of patients, further spurs an
interest in identifying predictive factors capable of driving
toward the most appropriate therapeutic strategy.
Our findings support evidence showing that the absenceof
at leasta6-monthbenefit inPFSwith first-line therapypredicts
a lack of benefit from subsequent therapeutic lines; however,
the results of our study have to be considered with caution
becauseofsomepotential pitfalls. Inparticular, thesample size
is small, and it is even smaller when considering patients
progressing to subsequent lines of treatment. Despite these
limitations, our analysis is one of the few evaluating outcome
across multiple lines of treatment for MBC. Future studies
following this approach could be used for proper allocation
of resources, considering both ASCO’s suggestions [12] and
the growing number of reports in favor of early integration of
supportive care for patients with advanced disease [21, 22].
Interestingly, in our study, the ability to predict therapeutic
benefit on thebasis of previous treatmentperformancedoesnot
seem to apply equally to the different subgroups (supplemental
online Fig. 2) or to different treatments (CTor ET).
PatientswithHR-positivediseasewhodidnotrespondtofirst-
line treatmentmight still gainbenefit fromsubsequenttherapies,
althoughwe cannot rule out that this effect is due to chance.The
basis of endocrine therapy resistance has been well studied in
luminal subtypes. Some resistance mechanisms that potentially
influence treatment response have been identified. Several data
are available about the activity of endocrine treatments in lines
beyond the first. Fulvestrant and anastrozole demonstrated ef-
ficacy in women whose BC had progressed following tamoxifen
[23, 24]. The phase III trial EFECT also demonstrated activity of
fulvestrant or exemestane in patients who failed treatment with
nonsteroidal aromatase inhibitors (NSAIs) [25]. More recently,
data from the BOLERO-2 trial showed efficacy of exemestane in
combination with everolimus in HR-positive, HER2-negative
patients who progressed to NSAIs [26, 27].
Notably, patients with HER2-positive disease who did not
show any response to first-line treatment were less likely to
respond to subsequent lines; such behavior could be explained
by the presence of de novo resistance. Our findings are in line
with those recently reported by Murthy et al., who analyzed
a series of 513 consecutive patients with HER2-positive MBC
treated with trastuzumab as part of first-line treatment [28].
The authors observed that women with prior exposure to
trastuzumab as part of their treatment for early BC had less
clinical benefit from trastuzumab than trastuzumab-naive
patients. In addition, in the phase III trial CLEOPATRA, patients
with de novo disease had a median PFS of 21.6 months,
whereas trastuzumab-pretreatedpatientshadamedianPFSof
16.9 months [29, 30].
In our series, the interpretation of the results about anti-
HER2 treatment requires caution because of the marginal use
of new agents potentially capable to overcome trastuzumab
resistance [31, 32]. In fact, ado-trastuzumab emtansine [33, 34]
orthecombinationof lapatinibandtrastuzumab[35]has shown
efficacy in patients with pretreated HER2-positive disease.
Moreover, because of the small sample size and the re-
trospectivedesign,thepresent studydoesnotallowtestingthe
effect of maintenance endocrine therapy after chemotherapy.
Because maintenance therapy is largely considered as an
available strategy to improve OS [36], this represents an im-
portant need to explore prospectively.
In summary, in our study, the absence of at least a 6-month
benefit for PFS with first-line therapy predicts a lack of benefit
from subsequent therapeutic lines; however, PPS does not
seem to be influenced by the benefit obtained at first line.
Accordingly, it couldbehypothesized that linesbeyondthe first
may have an impact on subsequent outcome. These results
mayexplain the lowcorrelationbetweenPFSwith first line and
OS when a long PPS is observed [15, 37].
CONCLUSION
In the era of precision medicine [38], this study provides further
evidence of the lack of predictive factors that can be used for
therapeutic choices in patients withmetastatic breast cancer and
emphasizes the urgent need to identify biomarkers that could
optimize therapeutic strategy. Targeted and nontargeted agents
should be tested in clinical trials with ad hoc translational design.
To achieve medical utility, modern clinical trials should not
only consider drug effectiveness. In fact, the identification of a
companion diagnostic capable of driving benefit estimation and
clinical decisionmaking is necessary and equally relevant [39].
Sharpeningthedefinitionof thetargetpopulation isofpivotal
importance in adopting the optimal upfront therapy. Similarly,
each subsequent treatment should be based on evaluation of
agent- and line-specific predictive factors. Finally, to understand
the ultimate effect of a therapeutic strategy (i.e., use of distinct
drugs in the first lineandbeyond), a clinical trial shouldbebuilt to
provide adequate information about the treatment sequence.
Results from such studies are eagerly awaited [40].
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